liposomal irinotecan + oxaliplatin + S-1

This is a **combination regimen** consisting of **liposomal irinotecan**, **oxaliplatin**, and **S-1**. Liposomal irinotecan is a pegylated liposomal formulation of irinotecan, a topoisomerase-I inhibitor that disrupts DNA replication in tumor cells by stabilizing the topoisomerase-I-DNA complex, leading to DNA strand breaks and cell death. The encapsulation prolongs drug circulation, enhances tumor targeting via the enhanced permeability and retention (EPR) effect, and provides a better safety and pharmacokinetic profile than conventional irinotecan. Oxaliplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis. S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug of 5-FU), gimeracil (a dihydropyrimidine dehydrogenase inhibitor to prolong 5-FU exposure), and oteracil (to reduce gastrointestinal toxicity). This combination is being explored as an adjuvant and metastatic therapy for pancreatic ductal adenocarcinoma and other digestive system malignancies, aiming to leverage the synergy of these agents. Clinical studies indicate a manageable safety profile and promising efficacy in pancreatic cancer[1][3][5].

Other names

NALIRI-SOX